A Phase 3 interventional study of No Intervention in Alzheimers Disease, sponsored by Hoffmann-La Roche. Recruiting at 234 sites in 15 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Screening
Among 40 studies in Alzheimer Disease by Hoffmann-La Roche — 3 open to participants now, 8 under way, 4 of them phase 3. Alzheimer Disease · Hoffmann-La Roche.
Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, this one has the largest planned enrollment, is one of 3 that started in 2025, is one of 14 in phase 3, and was the 37th registered.
3,967 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →3 of the 40 studies in Alzheimer Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Australia, France
Ages 50–90
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 7 more countries
Ages 55–80
By country, each count listing its studies:
Of the 642 Alzheimer Disease studies recruiting now, 283 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 284 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 13 · Phase 3 14
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80,000 is above the median of 70 across 3,020 interventional studies indexed under Alzheimer Disease.
Median enrollment 247 across the 40 interventional studies. Of the 32 that completed or were terminated, 18 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,101 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Alzheimer Disease by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06402838Hoffmann-La RocheA Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | 2026-11-19 |
| NCT07234942Hoffmann-La RocheA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) | 2027-03-31 |
| NCT04639050Hoffmann-La RocheBrainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be assessed for their concentration of pTau217 in blood and cognitive score in the International Shopping List Test (ISLT).
Other: No Intervention
Participants will have their blood drawn and cognitive score measured by the ISLT.
Concentration of pTau217 in Blood on Day1
Time frame: Day 1
Cognitive score in ISLT on Day 1
Time frame: Day 1
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 234 sites across 15 countries. Choose a country and city above to see the rest.
Plan to share: No
Started Jul 2025 (actual). Primary completion is estimated for Jul 2035, 120 months after the start.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 120 months is above that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.